BioLineRx Ltd. (NASDAQ: BLRX) today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Equity Offerings

BioLineRx (BLRX) Prices $15.4 Million Offering of its American Depositary Shares and WarrantsFebruary 5, 2019 9:04 AM BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and WarrantsFebruary 4, 2019 5:45 PM After-Hours Movers 02/04: (STX) Higher; (OPK) (HLIT) (GOOGL) (more...)February 4, 2019 5:28 PM BioLineRx (BLRX) Plans Offering of ADSs and WarrantsFebruary 4, 2019 4:43 PM BioLineRx (BLRX) Announces Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic CancerFebruary 4, 2019 7:09 AM